Molecular staging and the selection of therapy for non-small cell lung cancer

Seminars in Thoracic and Cardiovascular Surgery

Volumn 17, Issue 3, 2005, Pages 180-185

  D'Amico, Thomas A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lung cancer; Molecular biology; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; PRINOMASTAT; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT VASCULOTROPIN; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL ADHESION; CELL INVASION; CLINICAL TRIAL; DRUG FATALITY; DRUG POTENTIATION; EXTRACELLULAR MATRIX; HEMOPTYSIS; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; NONHUMAN; PROGNOSIS; RISK ASSESSMENT; SIDE EFFECT; TREATMENT FAILURE; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 27744590938     PISSN: 10430679     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semtcvs.2005.06.011     Document Type: Article

References (43)

1. Jemal A, Murray T, Ward E, et al: Cancer Statistics 2005. Ca Cancer J Clin 55:10-30, 2005
2. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111:1710-1717, 1997
3. Naruke T, Tsuchiya R, Kondo H, et al: Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: The Japanese experience. Ann Thorac Surg 71:1759-1764, 2001
4. Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology. JNCCN 2:94-124, 2004
5. Arriagada R, Bergman B, Dunant A, et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351-360, 2004
6. Strauss GM, Herndon J, Maddus A, et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer (NSCLC): Report of cancer and leukemia group B (CALGB) protocol 9633 [abstract]. Proc Am Soc Clin Oncol no. 7019, 2004
7. Winton TL, Livingston R, Johnson D, et al: A prospective randomized trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage IB and II non-small-cell lung cancer (NSCLC) intergroup JBR 10 [abstract]. Proc Am Soc Clin Oncol no. 7018, 2004
8. D'Cunha J, Corfits AL, Herndon JE 2nd, et al: Molecular staging of lung cancer: Real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small-cell lung cancer - preliminary results of cancer and leukemia group B trial 9761. J Thorac Cardiovasc Surg 123:484-491, 2002
9. Chen G, Gharib TG, Wang H, et al: Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A 100:13537-13542, 2003
10. Granville CA, Dennis PA: An overview of lung cancer genomics and proteomics. Am J Respir Cell Molec Biol 32:169-176, 2005
11. D'Amico TA, Massey M, Herndon JE, et al: A biological risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with use of ten molecular markers. J Thorac Cardiovasc Surg 117:736-743, 1999
12. D'Amico TA, Aloia TA, Herndon JE, et al: Molecular biologic substaging in patients with stage I non-small-cell lung cancer: Risk stratification according to gender and histologic subtype. Ann Thorac Surg 69:882-886, 2000
13. Harpole DH Jr, Herndon JE 2nd, Young WG, et al: Stage I non-smallcell lung cancer: A multivariate analysis of treatment methods and patterns. Cancer 76:787-796, 1995
14. Harpole DH Jr, Herndon JE 2nd, Wolfe WG, et al: A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55:51-56, 1995.
15. Harpole DH Jr, Richards WG, Herndon JE 2nd, et al: Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61:1470-1476, 1996
16. K.R. Brooks K. To M. Moore-Joshi et al. Measurement of chemotherapy resistance markers in patients with stage III non-small cell lung cancer: A novel approach to patient selection Ann Thorac Surg 76 2003 187-193
17. C.L. Lau T.A. D'Amico D.H. Harpole Staging and prognosis clinical and molecular prognostic factors and models for non-small cell lung cancer in: H.I. Pass J.B. Mitchell D.H. Johnson (eds) Lung cancer principles and practice ed 2 2000 Williams and Wilkins Philadelphia, Lippincott 612-627
18. J.A. Kern D.A. Schwartz J.E. Nordberg et al. P185neu expression in human lung adenocarcinoma predicts shortened survival Cancer Res 50 1990 5184-5187
19. C.J. Langer Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: Focus on NSCLC Int J Radiat Oncol Biol Phys 58 2004 991-1002
20. G. Giaccone R.S. Herbst C. Manegold et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1 J Clin Oncol 22 2004 777-784
21. R.S. Herbst G. Giaccone J.H. Schiller et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 2004 785-794
22. R.S. Herbst D. Prager R. Hermann et al. TRIBUTE - a phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 2004 no. 7011
23. U. Gatzemeier A. Pluzanska A. Szezesna et al. Results of a phase III trial of erlotinib (OSI-744) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 2004 no. 7010
24. F.A. Shepherd J. Pereira T.E. Ciuleanu et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial [abstract] Proc Am Soc Clin Oncol 2004 no. 7022
25. C.J. Langer P. Stephenson A. Thor et al. Trastuzumab in the treatment of advanced non-small-cell lung cancer: Is there a role? Focus on Eastern Cooperative Oncology Group Study 2598 J Clin Oncol 22 2004 1180-1187
26. U. Gatzemeier G. Groth C. Butts et al.Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer Ann Onc 15 2004 19-27
27. M. Hamada T. Fujiwara A. Hizuta et al. The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers J Cancer Res Clin Oncol 122 1996 360-365
28. S.T. Szak J.A. Pietenpol High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain J Biol Chem 274 1999 3904-3909
29. S.G. Swisher J.A. Roth R. Komaki et al. A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 19 2000 461a no. 1807)
30. M. Schuler R. Hermann J.L.P. De Greve et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study J Clin Oncol 19 2001 1750-1758
31. G.K. Dy A.A. Adjei Novel targets for lung cancer therapy: Part II J Clin Oncol 20 2002 3016-3028
32. E. Fosslien Molecular pathology of cyclooxygenase-2 in neoplasia Ann of Clin Lab Science 30 2000 3-21
33. S.A. Wardlaw T.H. March S.A. Belinsky Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions Carcinogenesis 21 2000 1371-1377
34. T. Hida K. Kozaki H. Muramatsu et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines Clin Cancer Res 6 2000 2006-2011
35. N.K. Altorki R.S. Keresztes J.L. Port et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer J Clin Oncol 21 2003 2645-2650
36. J.M. Schlaeppi J.M. Wood Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors Can Met Reviews 18 1999 473-481
37. H. Hurwitz L. Fehrenbacher T. Cartwright et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC [abstract] Proc Am Soc Clin Oncol 2003 22a (no. 3646)
38. R.F. DeVore L. Fehrenbacher R.S. Herbst et al. A randomized phase II trial comparing rhumAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC [abstract] Proc Am Soc Clin Oncol 19 2000 485a (no. 1896)
39. D.H. Johnson R. DeVore F. Kabbinavar et al. Carboplatin (C) + paclitaxel (P) + rhuMab-VEGF(AVF) may prolong survival in advanced non-squamous lung cancer [abstract] Proc Am Soc Clin Oncol 20 2001 315a (no. 1256)
40. M. Hidalgo S.G. Eckhardt Development of matrix metalloproteinase inhibitors in cancer therapy J Natl Cancer Inst 93 2001 178-193
41. F.A. Shepherd G. Giaccone C. Debruyne et al. Randomized double-blind placebo-controlled trial of marimastat in patients with small cell lung cancer (SCLC) following response to first-line chemotherapy: An NCIC-CTG and EORTC study [abstract] Proc Am Soc Clin Oncol 20 2001 4a (no. 11)
42. M. Smylie R. Mercier D. Aboulafia et al. Phase III study of the matrix metalloprotease (MMP) inhibitor prinomastat in patients having advanced non-small cell lung cancer (NSCLC) [abstract] Proc Am Soc Clin Oncol 20 2001 307a (no. 1226)
43. N.B. Leighl L. Shepherd F Paz-Ares J.-Y. Douillard et al. Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18 J Clin Oncol 22 14S 2004 7038